Biyolojik ajan tedavisi alan ve almayan romatoid artritli hastaların modifiye charlson komorbidite indekslerinin karşılaştırılması
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Hatay Mustafa Kemal Üniversitesi Hastanesi Romatoloji ve İç Hastalıkları polikliniğine başvuran RA'lı hastaların biyolojik ajan kullanım durumunu Charlson Komorbidite İndeksiyle (CCI) karşılaştırmayı amaçladık. Gereç ve yöntem: Biyolojik ajan kullanan 50 hasta ve biyolojij ajan kullanmayan 50 hasta çalışmaya dahil edildi. Biyolojik ajan alan ve almayan gruba aynı anket uygulandı ve katılımcıların sosyodemografik özellikleri, hastalık süresi ve aktif tedavi süresi, kullandıkları ilaçlar ve bu grup ilaçları kullanma süreleri, hastaların hastaneye başvurularındaki laboratuar değerleri kaydedildi. Bunlar dışında hastalara DAS28 (Disease Activity Score) ölçeği, HAQ (Health Assessment Questionnaire) ölçeği ve Modifiye Charlson Komorbidite Ölçeği uygulandı. Verilerin analizi SPSS 21 programı ile yapıldı. Bulgular: Her iki grubun hastalık süresi değerlendirildiğinde; biyolojik ajan alan grupta ortalama hastalık süresi 11±6.1 olarak, biyolojik ajan almayan grupta ortalama hastalık süresi 6.3±6.7 olarak hesaplandı ve istatiksel olarak anlamlı bir fark vardı (p<0.001). CCI skoru biyolojik ajan alan grupta ortalama 3.14(±2.03), biyolojik ajan almayan grupta ortalama 2.24(±1.66) olarak olarak hesaplandı ve biyolojik ajan alan ve almayan gruplar karşılaştırıldığında istatiksel olarak anlamlı bir fark bulundu (p=0.024). Sonuç: RA'nın birçok kötü prognoz kritenin olduğu ve CCI skorunun yüksekliğinin bu kötü prognoz kriterleri arasında yer alabileceğini düşündük. Komorbidite fazlalığının hastaları daha komplike tedavi almaya sürüklediği ve aktif tedavi süresini, tedavi gecikmesini uzatabileceği sonucuna vardık. CCI skoru yüksek olan hastaların biyolojik ajan gereksiniminin ilerlerleyen yıllarda artabileceği, hastalık aktivite skorları olan DAS28 ve HAQ skorunu arttırabileceği ve bunun biyolojik ajan kullanımından bağımsız olarak yüksek olabileceği sonucuna vardık.
Aim: In this study, we aimed to compare the use of biological agents with the Charlson Comorbidity Index (CCI) in patients with RA who applied to the Hatay Mustafa Kemal University Rheumatology and Internal Medicine outpatient clinic. Material and Methods: Fifty patients using biological agents and 50 patients not using biological agents were included in the study. The same questionnaire was applied to the group that received and did not receive biologic agents, and the sociodemographic characteristics of the participants, the duration of the disease and the duration of active treatment, the drugs they used and the duration of using this group of drugs, and the laboratory values of the patients at the hospital admission were recorded. Apart from these, DAS28 (Disease Activity Score), HAQ (Health Assessment Questionnaire) and Modified Charlson Comorbidity Scale were applied to the patients. Data analysis was done with SPSS 21 program. Results: When the disease duration of both groups is evaluated; The mean duration of disease was 11±6.1 in the group that received biologic agents, and 6.3±6.7 in the group that did not receive biologic agents, and there was a statistically significant difference (p<0.001). The mean CCI score was calculated as 3.14 (±2.03) in the group that received biological agents, and 2.24 (±1.66) in the group that did not receive biological agents, and a statistically significant difference was found when the groups that received and did not receive biological agents were compared (p=0.024). Conclusion: We thought that RA has many poor prognostic criteria and a high CCI score may be among these poor prognosis criteria. We concluded that excess comorbidity may lead patients to receive more complicated treatment and may prolong the active treatment period and treatment delay. We concluded that the need for biological agents in patients with a high CCI score may increase in the following years, may increase the disease activity scores of DAS28 and HAQ, and this may be high regardless of the use of biological agents. Key words: Anti-TNFα, Biological Agent Therapy, Charlson Comorbidity Index, DMARD, Rheumatoid Arthritis
Aim: In this study, we aimed to compare the use of biological agents with the Charlson Comorbidity Index (CCI) in patients with RA who applied to the Hatay Mustafa Kemal University Rheumatology and Internal Medicine outpatient clinic. Material and Methods: Fifty patients using biological agents and 50 patients not using biological agents were included in the study. The same questionnaire was applied to the group that received and did not receive biologic agents, and the sociodemographic characteristics of the participants, the duration of the disease and the duration of active treatment, the drugs they used and the duration of using this group of drugs, and the laboratory values of the patients at the hospital admission were recorded. Apart from these, DAS28 (Disease Activity Score), HAQ (Health Assessment Questionnaire) and Modified Charlson Comorbidity Scale were applied to the patients. Data analysis was done with SPSS 21 program. Results: When the disease duration of both groups is evaluated; The mean duration of disease was 11±6.1 in the group that received biologic agents, and 6.3±6.7 in the group that did not receive biologic agents, and there was a statistically significant difference (p<0.001). The mean CCI score was calculated as 3.14 (±2.03) in the group that received biological agents, and 2.24 (±1.66) in the group that did not receive biological agents, and a statistically significant difference was found when the groups that received and did not receive biological agents were compared (p=0.024). Conclusion: We thought that RA has many poor prognostic criteria and a high CCI score may be among these poor prognosis criteria. We concluded that excess comorbidity may lead patients to receive more complicated treatment and may prolong the active treatment period and treatment delay. We concluded that the need for biological agents in patients with a high CCI score may increase in the following years, may increase the disease activity scores of DAS28 and HAQ, and this may be high regardless of the use of biological agents. Key words: Anti-TNFα, Biological Agent Therapy, Charlson Comorbidity Index, DMARD, Rheumatoid Arthritis
Açıklama
Anahtar Kelimeler
İç Hastalıkları, Internal diseases, Anti-TNFα, Biyolojik Ajan Tedavisi, Charlson Komorbidite İndeksi, DMARD, Romatoid Artrit
